Moderna stock has plunged more than 15% this year, with its shares plunging by a staggering 2,700% in 2017.
The news is likely to fuel fears among investors that the Italian firm, which has been the subject of criticism for the treatment of migrant workers, is nearing the end of a run of bad results and will likely have to raise the cost of its stock.
The latest losses came after the stock fell by more than 4,000% in the past five years.
It’s not the first time the Italian company has suffered from bad news.
It suffered a series of massive losses during the financial crisis, and it’s been heavily criticised for being the poster child for Italy’s financial problems.
A recent poll showed a clear majority of Italians view the company as bad, with more than 90% of respondents having a negative opinion of the company.